Lab21 Company Profile
Lab21 is a global leader in personalised healthcare. It provides diagnostic products and services and supports blood bank screening, medical diagnostics and drug discovery. Lab21 customers include international healthcare providers, pharmaceutical and diagnostic companies. The Products division of Lab21 manufactures immunodiagnostic kits and reagents that are distributed internationally and is focused on infectious diseases for the blood-banking and clinical markets. Our clinical services operations has a growing test portfolio providing companion diagnostics and high technology molecular assays. Lab21's corporate offices are based in Cambridge, UK and South Carolina, with a GMP manufacturing site in Cambridge and other manufacturing facilities in Newmarket, Camberley and Bridport. The Company's investors include Excalibur, Nexus Medical Partners and Medicis Capital. Website: www.lab21.com
News Articles
Lab21 Announces Sale of South Carolina Operations.
Cambridge, UK – 8 January 2013 - Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the sale of its laboratory operations based in South...
Lab21 Announces Sale of South Carolina Operations
Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the sale of its laboratory operations based in South Carolina to Reedy Acqu...
Reedy Acquisitions agrees to buy Lab21 South Carolina laboratory operations
Reedy Acquisitions has agreed to buy South Carolina-based laboratory operations of Lab21, which provides diagnostic products and services.
Mystery pharma signs Lab21 for colorectal cancer companion diagnostics
UK personalised medicine firm Lab21 has partnered with a "world-leading" pharma company to develop a new companion diagnostic for use in colorectal cancer. The Cambridge company would not disclose its...
Cambridge, UK – 20 February 2012 - Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the appointment of Fraser Logue as Group Director...
Lab21 Wins Biomedical Project of the Year Award
Cambridge, UK – 29 November 2011 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has won the prestigious BioNow Biomedical Project of the Year Awar...
Lab21 Launches New Lung Cancer Diagnostic Service
Cambridge, UK – 16 February 2012 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics has launched a new Companion Diagnostic testing service for non-sm...
Lab21 receives regulatory approval for Campylobacter assay in China
Cambridge, UK – 13 December 2011 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, today announced that it has received regulatory approval for its M...
Drugs and Medications
None
PubMed Articles
BACKGROUND: Prevention of transfusion-transmitted malaria in at-risk children and pregnant women in endemic areas with inexpensive chloroquine is no longer effective due to widespread drug resistance....
Clinical Trials
None
Companies
Lab21 is a global leader in personalised healthcare. It provides diagnostic products and services and supports blood bank screening, medical diagnostics and drug discovery. Lab21...
More Information about "Lab21" on BioPortfolio
We have published hundreds of Lab21 news stories on BioPortfolio along with dozens of Lab21 Clinical Trials and PubMed Articles about Lab21 for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lab21 Companies in our database. You can also find out about relevant Lab21 Drugs and Medications on this site too.
